Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1771 to 1785 of 7682 results

  1. STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]

    Awaiting development [GID-TA10279] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Rivaroxaban for treating chronic heart failure [ID1462]

    Awaiting development [GID-TA10393] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]

    In development [GID-TA10919] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]

    In development [GID-TA10998] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237

    Awaiting development [GID-TA11328] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Levodopa, carbidopa monohydrate and entacapone intestinal gel for treating the symptoms of advanced Parkinson's disease [ID4005]

    Suggested remit: To appraise the clinical and cost effectiveness of levodopa, carbidopa monohydrate and entacapone within its marketing authorisation for treati...

    Technology appraisal guidance
    Topic selection

  7. Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide TS ID 10046

    Awaiting development [GID-TA11335] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Bimekizumab for treating ankylosing spondylitis TS ID 10334

    Awaiting development [GID-TA11150] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 TS ID 11848

      Status ...

    Technology appraisal guidance
    Topic selection

  10. Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer TS ID 11861

    Awaiting development [GID-TA11345] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa TS ID 10592

    Awaiting development [GID-TA11332] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over TS ID 9130

    Awaiting development [GID-TA11325] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Galcanezumab for migraine TS ID 10663

    Awaiting development [GID-TA11311] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Infection prevention and control update

    In development [GID-QS10177] Expected publication date: TBC

    Quality standard
    In development

  15. Elexacaftor–tezacaftor–ivacaftor and ivacaftor for treating cystic fibrosis with at least 1 F508del mutation in the CFTR gene in children aged 2 to 5 TS ID 10767

      Status ...

    Technology appraisal guidance
    Topic selection